Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 20/20 | 0.83 |
| ▸ | PSMB8 | P28062 | 9/20 | 0.83 |
| ▸ | PSMB9 | P28065 | 9/20 | 0.83 |
| ▸ | PSMB6 | P28072 | 9/20 | 0.83 |
| ▸ | PSMB10 | P40306 | 9/20 | 0.83 |
| ▸ | PSMB11 | A5LHX3 | 8/20 | 0.83 |
| ▸ | PSMA7 | O14818 | 8/20 | 0.83 |
| ▸ | PSMB1 | P20618 | 8/20 | 0.83 |
| ▸ | PSMA1 | P25786 | 8/20 | 0.83 |
| ▸ | PSMA2 | P25787 | 8/20 | 0.83 |
| ▸ | PSMA3 | P25788 | 8/20 | 0.83 |
| ▸ | PSMA4 | P25789 | 8/20 | 0.83 |
| ▸ | PSMA5 | P28066 | 8/20 | 0.83 |
| ▸ | PSMB4 | P28070 | 8/20 | 0.83 |
| ▸ | PSMB3 | P49720 | 8/20 | 0.83 |
| ▸ | PSMB2 | P49721 | 8/20 | 0.83 |
| ▸ | PSMA6 | P60900 | 8/20 | 0.83 |
| ▸ | PSMA8 | Q8TAA3 | 8/20 | 0.83 |
| ▸ | PSMB7 | Q99436 | 8/20 | 0.83 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL253626 | 0.91 | PSMB5 (1.00) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL4800634 | 0.89 | PSMB5 (0.78) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL4803733 | 0.89 | PSMB5 (0.76) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL252153 | 0.87 | PSMB5 (0.81) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL21841192 | 0.86 | PSMB5 (0.80) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL253976 | 0.86 | PSMB5 (0.75) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL10005139 | 0.83 | PSMB5 (0.59) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL253272 | 0.83 | PSMB5 (0.71) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL21841215 | 0.83 | PSMB5 (0.81) | PSMB5PSMB8PSMB9PSMB6PSMB10 | |
| SCHEMBL253622 | 0.83 | PSMB5 (0.83) | PSMB5PSMB8PSMB9PSMB6PSMB10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083922-A1 | Proteasome Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-03-14 | — | — | US | claimed |
| US-20230265110-A1 | Proteasome Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-08-24 | — | — | US | claimed |
| US-20220251117-A1 | PROTEASOME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2022-08-11 | — | — | US | claimed |
| US-20220017542-A1 | PROTEASOME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2022-01-20 | — | — | US | claimed |
| US-20210206784-A1 | PROTEASOME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2021-07-08 | — | — | US | claimed |
| US-20200407376-A1 | PROTEASOME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2020-12-31 | — | — | US | claimed |
| US-20200190118-A1 | PROTEASOME INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2020-06-18 | — | — | US | claimed |
| US-20190144470-A1 | PROTEASOME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-16 | — | — | US | claimed |
| US-20180305380-A1 | PROTEASOME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-25 | — | — | US | claimed |
| US-20180099984-A1 | PROTEASOME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-04-12 | — | — | US | claimed |
| EP-2560647-B1 | COMBINATION THERAPY WITH A PROTEASOME INHIBITOR AND A GALLIUM COMPLEX | NIIKI PHARMA INC (US) | 2016-04-13 | — | — | EP | claimed |
| US-20150361105-A1 | PROTEASOME INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-17 | — | — | US | claimed |
| US-20150011506-A1 | Proteasome Inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-08 | — | — | US | claimed |
| US-8871745-B2 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | claimed |
| US-20130331356-A1 | Proteasome Inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2013-12-12 | — | — | US | claimed |
| US-20130096068-A1 | COMBINATION THERAPY WITH A PROTEASOME INHIBITOR AND A GALLIUM COMPLEX | NIIKI PHARMA INC. (US) | 2013-04-18 | — | — | US | claimed |
| EP-2527347-A1 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-11-28 | — | — | EP | claimed |
| EP-2178888-B1 | PROTEASOME INHIBITORS | MILLENNIUM PHARM INC (US) | 2012-07-04 | — | — | EP | claimed |
| US-7442830-B1 | Proteasome inhibitors | MILLENIUM PHARMACEUTICALS, INC. (US) | 2008-10-28 | — | — | US | claimed |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2023-01-03 | — | — | US | disclosed |
| EP-3125920-B1 | DIANHYDROGALACTITOL, DIACETYLDIANHYDROGALACTITOL OR DIBROMODULCITOL TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2020-12-23 | — | — | EP | disclosed |
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2019-09-05 | — | — | US | disclosed |
| US-20180140571-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | BACHA JEFFREY (CA) | 2018-05-24 | — | — | US | disclosed |
| EP-3294284-A1 | COMBINATION OF ANALOGS OR DERIVATIVES OF DIANHYDROGALACTITOL WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT CANCER | Delmar Pharmaceuticals, Inc. (CA) | 2018-03-21 | — | — | EP | disclosed |
| EP-3210987-A1 | PROCESS FOR THE SYNTHESIS OF PROTEASOME INHIBITORS | Millennium Pharmaceuticals, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-3125920-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | Del Mar Pharmaceuticals (CA) | 2017-02-08 | — | — | EP | disclosed |
| WO-2016183331-A1 | COMBINATION OF ANALOGS OR DERIVATIVES OF DIANHYDROGALACTITOL WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT CANCER | DELMAR PHARMACEUTICALS, INC. (CA) | 2016-11-17 | — | — | WO | disclosed |
| EP-2560647-B1 | COMBINATION THERAPY WITH A PROTEASOME INHIBITOR AND A GALLIUM COMPLEX | NIIKI PHARMA INC (US) | 2016-04-13 | — | — | EP | disclosed |
| US-20160008316-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DEL MAR PHARMACEUTICALS (CA) | 2016-01-14 | — | — | US | disclosed |
| WO-2015154064-A2 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND OVARIAN CANCER | DEL MAR PHARMACEUTICALS (CA) | 2015-10-08 | — | — | WO | disclosed |
| US-20130096068-A1 | COMBINATION THERAPY WITH A PROTEASOME INHIBITOR AND A GALLIUM COMPLEX | NIIKI PHARMA INC. (US) | 2013-04-18 | — | — | US | disclosed |
| EP-2527347-A1 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-11-28 | — | — | EP | disclosed |
| EP-2527347-A1 | Proteasome inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (18 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331356-A1 | Proteasome Inhibitors | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20150011506-A1 | Proteasome Inhibitors | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20180305380-A1 | PROTEASOME INHIBITORS | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20240083922-A1 | Proteasome Inhibitors | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20220251117-A1 | PROTEASOME INHIBITORS | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20180099984-A1 | PROTEASOME INHIBITORS | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20190269646-A9 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | PSMB5 2618/4885PSMB8 1764/4885PSMB9 2920/4885 |
| US-20190144470-A1 | PROTEASOME INHIBITORS | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20210206784-A1 | PROTEASOME INHIBITORS | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20130096068-A1 | COMBINATION THERAPY WITH A PROTEASOME INHIBITOR AND A GALLIUM COMPLEX | PSME1, PSMB5, PSMB1 | PSMB5 2/4885PSMB8 32/4885PSMB9 28/4885 |
| US-20220017542-A1 | PROTEASOME INHIBITORS | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20180140571-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | PSMB5 2618/4885PSMB8 1764/4885PSMB9 2920/4885 |
| US-20230265110-A1 | Proteasome Inhibitors | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20200407376-A1 | PROTEASOME INHIBITORS | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20150361105-A1 | PROTEASOME INHIBITORS | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
| US-20160008316-A1 | USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES | DNMT1, MGMT, DCK | PSMB5 2618/4885PSMB8 1764/4885PSMB9 2920/4885 |
| US-11541027-B2 | Use of dianhydrogalactitol and analogs or derivatives thereof in combination with platinum-containing antineoplastic agents to treat non-small-cell carcinoma of the lung and brain metastases | DNMT1, MGMT, DCK | PSMB5 2618/4885PSMB8 1764/4885PSMB9 2920/4885 |
| US-20200190118-A1 | PROTEASOME INHIBITORS | PSMB5, PSMG3, PSMB1 | PSMB5 1/4885PSMB8 32/4885PSMB9 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.